Journals / Journal of Health Sciences and Medicine / 2022 / Cilt: 5 - Sayı: 5

Evaluation of the impact of platelet-rich plasma in women with reduced ovarian reserve

Pages
1334–1338
Publication Date
2022-09-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The mean AMH levels before and after the injection were 0.07±0.05 and 0.13±0.06, respectively (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Infertility is the most critical factor disrupting the marital relationship, which imposes high financial and psychological costs on couples.
📊
Key Findings & Data:Material and Method: In this study, 40 women with a history of infertility with a mean age of 37.75 were included in the study.
💡
Conclusion & Impact:Results: The mean AMH levels before and after the injection were 0.07±0.05 and 0.13±0.06, respectively (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Infertility · platelet-rich plasma · follicle-stimulating hormone

Abstract

Introduction: Infertility is the most critical factor disrupting the marital relationship, which imposes high financial and psychological costs on couples. Despite vast advances, the problem of infertility has not yet been entirely resolved. The new method of injecting platelet-rich plasma (PRP) has been promising for couples. This study investigated the effect of PRP injection on the fertility of infertile women. Material and Method: In this study, 40 women with a history of infertility with a mean age of 37.75 were included in the study. Prior to the demographic information intervention, laboratory findings, including serum anti-mullerian hormone (AMH) levels and ultrasound for the number of antral follicles count (AFC) were performed. Autologous PRP was then prepared for each patient, and an intraovarian injection was performed. Two months after injection, serum levels of AMH and AFC levels were re-evaluated. Results: The mean AMH levels before and after the injection were 0.07±0.05 and 0.13±0.06, respectively (p

🔖

Cite This Article

GÜRKAN, N., GÜNGÖR, N. D., MADENLİ, A. A., TOSUN, Ş. A. (2022). Evaluation of the impact of platelet-rich plasma in women with reduced ovarian reserve. Journal of Health Sciences and Medicine, Cilt: 5 - Sayı: 5, 1334–1338. https://ajindex.com/articles/776457

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Brandt JS, Cruz Ithier MA, Rosen T, Ashkinadze E. Advanced paternal age, infertility, and reproductive risks: A review of the literature. Prenat Diagn 2019; 39: 81-7. Jirge PR. Poor ovarian reserve. Journal of human reproductive sciences 2016; 9: 63. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Committee Opinion No. 589. Fertil Steril 2014; 101: 633-4.
  2. Jabeen F, Khadija S, Daud S. Prevalence of Primary and Secondary Infertility. Saudi J Med 2022; 7: 22-8.
  3. Iino K, Fukuhara R, Yokota M, Yokoyama Y. Fertility awareness and subclinical infertility among women trying to get pregnant at home. BMC Womens Health 2022; 22:43. Seli E. Ovarian Aging. Semin Reprod Med 2015; 33: 375-6.
  4. Carson SA, Kallen AN. Diagnosis and Management of Infertility: A Review. JAMA 2021; 326: 65-76.
  5. Donders GGG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother 2019; 20: 821-35.
  6. Quaas, AM, Legro RS. Pharmacology of medications used for ovarian stimulation. Best Pract Res Clin Endocrinol Metab 2019; 33: 21-33. Sánchez-González DJ, Méndez-Bolaina E, Trejo-Bahena NI. Platelet-rich plasma peptides: key for regeneration. Int J Pept 2012; 2012: 532519. Sharara FI, Lelea LL, Rahman S, Klebanoff JS, Moawad GN. A narrative review of platelet-rich plasma (PRP) in reproductive medicine. J Assist Reprod Genet 2021; 38: 1003-12.
  7. Coksuer, H, Akdemir Y, and Ulas Barut M. Improved in vitro fertilization success and pregnancy outcome with autologous platelet-rich plasma treatment in unexplained infertility patients that had repeated implantation failure history. Gynecological Endocrinol 2019; 35: 815-8.
  8. Stojkovska S, Gligor D, Petanovski, et al. Novel method of treating ovarian infertility: is platelet-rich plasma a new promising therapy in the future? Macedonian Med Rev 2019; 73: 101-5.
  9. Sills ES, Rickers NS, Li X, Palermo GD. First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma. Gynecol Endocrinol 2018; 34: 756-60.
  10. Sills ES, Rickers NS, Petersen JL, Li X, Wood SH. Regenerative effect of intraovarian injection of autologous platelet rich plasma: Serum anti-Mullerian hormone levels measured among poor-prognosis in vitro fertilization patients. Int J Regen Med 2020; 3: 1-5.
  11. Sfakianoudis K, Simopoulou M, Nitsos N, et al. A Case series on plate